Literature DB >> 30647181

Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency.

Antonella Insalaco1,2, Gian Marco Moneta3,4, Manuela Pardeo3,4, Ivan Caiello3,4, Virginia Messia3,4, Claudia Bracaglia3,4, Chiara Passarelli3,4, Fabrizio De Benedetti3,4.   

Abstract

OBJECTIVE: An upregulation of type I interferon (IFN) stimulated genes [IFN score (IS)] was described in patients with adenosine deaminase 2 deficiency (DADA2). We describe the clinical course of 5 such patients and the role of IS as a marker of disease activity and severity.
METHODS: Expression levels of IS were determined by quantitative real-time PCR.
RESULTS: Five white patients were identified as carrying CECR1 mutations. The IS before treatment was elevated in 4 out of 5 patients and decreased after treatment.
CONCLUSION: Our data confirm the high variability of DADA2 and suggest type I IS as a biomarker of disease activity.

Entities:  

Keywords:  ADA2 DEFICIENCY; DISEASE BIOMARKER; INTERFERON

Year:  2019        PMID: 30647181     DOI: 10.3899/jrheum.180045

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

Review 1.  Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart.

Authors:  Zhengping Huang; Tianwang Li; Peter A Nigrovic; Pui Y Lee
Journal:  Clin Immunol       Date:  2020-04-07       Impact factor: 3.969

Review 2.  Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2).

Authors:  Pui Y Lee; Ivona Aksentijevich; Qing Zhou
Journal:  Semin Immunopathol       Date:  2022-02-17       Impact factor: 9.623

Review 3.  Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.

Authors:  Benzeeta Pinto; Prateek Deo; Susmita Sharma; Arshi Syal; Aman Sharma
Journal:  Clin Rheumatol       Date:  2021-03-31       Impact factor: 2.980

4.  Comparable type I interferon score determination from PAXgene and Tempus whole blood RNA collection and isolation systems.

Authors:  Lovro Lamot; Iwona Niemietz; Kelly L Brown
Journal:  BMC Res Notes       Date:  2019-08-15

5.  Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency.

Authors:  Stuart G Tangye; Isabelle Meyts; Jin Yan Yap; Leen Moens; Ming-Wei Lin; Alisa Kane; Anthony Kelleher; Catherine Toong; Kathy H C Wu; William A Sewell; Tri Giang Phan; Georgina E Hollway; Karen Enthoven; Paul E Gray; Jose Casas-Martin; Carine Wouters; Lien De Somer; Michael Hershfield; Giorgia Bucciol; Selket Delafontaine; Cindy S Ma
Journal:  J Clin Immunol       Date:  2021-10-17       Impact factor: 8.317

Review 6.  Druggable monogenic immune defects hidden in diverse medical specialties: Focus on overlap syndromes.

Authors:  Valentina Boz; Chiara Zanchi; Laura Levantino; Guglielmo Riccio; Alberto Tommasini
Journal:  World J Clin Pediatr       Date:  2022-03-09

7.  Lentiviral Mediated ADA2 Gene Transfer Corrects the Defects Associated With Deficiency of Adenosine Deaminase Type 2.

Authors:  Ying Hong; Marina Casimir; Benjamin C Houghton; Fang Zhang; Barbara Jensen; Ebun Omoyinmi; Robert Torrance; Charalampia Papadopoulou; Michelle Cummins; Marion Roderick; Adrian J Thrasher; Paul A Brogan; Despina Eleftheriou
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 8.  Vasculitis, Autoimmunity, and Cytokines: How the Immune System Can Harm the Brain.

Authors:  Alessandra Tesser; Alessia Pin; Elisabetta Mencaroni; Virginia Gulino; Alberto Tommasini
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

Review 9.  The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency.

Authors:  Jennifer Lee Kendall; Jason Michael Springer
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

Review 10.  Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity.

Authors:  Georgios Sogkas; Faranaz Atschekzei; Ignatius Ryan Adriawan; Natalia Dubrowinskaja; Torsten Witte; Reinhold Ernst Schmidt
Journal:  Cell Mol Immunol       Date:  2021-04-01       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.